X
[{"orgOrder":0,"company":"Pherin Pharmaceuticals","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vistagen to Acquire Pherin Pharmaceuticals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Pherin Pharmaceuticals","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Pherin Pharmaceuticals","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Pherin Pharmaceuticals
Filters
Companies By Therapeutic Area
Details:
PH80 is a first-in-class, rapid-onset product candidate, designed to be used in a manner analogous to a rescue inhaler for acute management of the symptoms of premenstrual dysphoric disorder.
Lead Product(s):
PH80
Therapeutic Area: Obstetrics/Gynecology (Women’s Health)
Product Name: PH80
Highest Development Status: Phase III
Product Type: Small molecule
Recipient:
VistaGen Therapeutics
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 12, 2023
Details:
Through the acquisition, Vistagen owns all intellectual property rights to PH94B (aloradine), in Phase 3 development for SAD and Phase 2 development for AjDA, and PH10, in clinical development for MDD, as well as three additional candidates in earlier stages of development.
Lead Product(s):
Fasedienol
Therapeutic Area: Psychiatry/Psychology
Product Name: PH94B
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
VistaGen Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Acquisition
February 02, 2023
Details:
PH94B (aloradine) is a first-in-class synthetic investigational neurosteroid developed from proprietary compounds called pherines. With its novel MOA, PH94B is a nasal spray designed to achieve rapid-onset anti-anxiety, or anxiolytic, effects.
Lead Product(s):
Fasedienol
Therapeutic Area: Psychiatry/Psychology
Product Name: PH94B
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
VistaGen Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Acquisition
December 21, 2022